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Available online xxxxIschemia-reperfusion injury (IRI) during renal transplantation often initiates non-speciﬁc inﬂammatory re-
sponses that can result in the loss of kidney graft viability. However, the long-term consequence of IRI on renal
grafts survival is uncertain. Herewe review clinical evidence and laboratory studies, and elucidate the association
between early IRI and later graft loss. Our critical analysis of previous publications indicates that early IRI does
contribute to later graft loss through reduction of renal functional mass, graft vascular injury, and chronic hyp-
oxia, as well as subsequent ﬁbrosis. IRI is also known to induce kidney allograft dysfunction and acute rejection,
reducing graft survival. Therefore, attempts have been made to substitute traditional preserving solutions with
novel agents, yielding promising results.
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Renal grafts inevitably experience ischemia from the moment they
are separated from the donor blood supply. The insult begins following
a period of transient surgical warm ischemia during donor organ
extraction, followed by a lengthy cold ischemic period in hypothermal
preserving solution before ending with warm ischemia during implanta-
tion in the recipient. After revascularization, blood ﬂow in post-ischemic
kidneys activates a sequence of events that aggravates renal injury. This
pathological phenomenon is described as ischemia-reperfusion injury
(IRI) and contributes to a high rate of morbidity. The severity of renal in-
sult correlates strongly with early renal graft failure. However, most
transplant patients completely recover from the initial IRI period. Clinical
evidence demonstrates that transplanted kidneys with prolonged ische-
mic time are more susceptible to long-term deterioration. We review
clinical studies, in order to elucidate the association between early IRI
and later graft loss, and discuss important concepts relating to the pathol-
ogy and prevention of graft dysfunction.
2. Survival of the Renal Grafts
With the introduction of potent immunosuppressive drugs such as
calcineurin inhibitors, acute rejection rates have fallen dramatically,
whilst allograft survival rates have risen steadily. Hariharan et al.
(2000) analyzed graft survival for 93,934 renal transplantations per-
formed in the USA between 1988 and 1996 and reported a marked im-
provement in the long-term survival of renal grafts from both living
and cadaveric donors. Over this period, the half-life of living donor grafts
increased from 12.7 to 21.6 years, and the half-life of cadaveric grafts in-
creased 7.9 to 13.8 years. These signiﬁcant improvements in graft survival
have been attributed to reﬁnement in kidney preservation and improve-
ments in peri-operative care and immunosuppressive medication.
Despite the continuous progress in immunosuppressive and support-
ive therapy, improvement in graft survival has reached aplateau. Thema-
jority of grafts eventually develop chronic dysfunctionwhich limits long-
term graft survival (Chapman et al., 2005). Histologically, chronic failure
is characterized by intimal thickening of arteries, glomerulosclerosis, tu-
bular interstitial ﬁbrosis, and tubular atrophy. Renal functional impair-
ment is often found in combination with proteinuria and aggravation of
de novo hypertension. These histological changes are thought to be the
end result of cumulative damage to renal grafts associated with both im-
mune and non-immune factors, however the precise etiological factors
underlying these changes remain to be elucidated (Nankivell and
Chapman, 2006). Renal graft IRImay be one of the critical factors contrib-
uting to deterioration in long-term graft survival.
3. Impact of IRI on Renal Graft Survival: Clinical Evidence
3.1. Ischemia Reperfusion Injury and Marginal Donor Organs
There are three main types of kidney donors: donation after brain
death (DBD) donors, donation after cardiac death (DCD) donors and liv-
ing donors. Another donor source is expanded criteria donation (ECD),
which includes DCD donors and those with particular co-morbidites
such as arterial hypertension or an age N 60 years (Iordanous et al.,
2009).Please cite this article as: Zhao, H., et al., Ischemia-Reperfusion Injury
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resuscitated or are awaiting cardiac death (Doyle et al., 2015). The
commonest type of organ transplantation in the UK is donation after
brain death (DBD), which is characterized by total and irreversible
loss of brain function (Robey andMarcolini, 2013). DBD is generally pre-
ferred over DCDbecause the graft is perfused until the point of organ re-
trieval. Whilst organs from DCD donors are subject to prolonged warm
ischaemic times, they may have a theoretic advantage. In DBD donors,
also known as heart-beating brain dead donors, brain death results in
a systemic inﬂammatory ‘cytokine storm’ (Vergoulas et al., 2009). The
body responds by increasing the release of circulating catecholamines,
resulting in a subsequent autonomic storm. This can precipitate pulmo-
nary oedema, hypertension, severe myocardial damage and microvas-
cular and parenchymal damage to the renal graft. Following this
period of intense autonomic activity, there is a dramatic fall in circulat-
ing catecholamines, resulting in vasodilation, bradycardia and tissue
hypoxia. Whilst DCD donors are also susceptible to this inﬂammatory
response, due to the rapidity of neuronal damage this is often to a
smaller extent than DBD donors (Mckeown et al., 2012). Due to a lack
of donors and the prevalence of graft failure, there has been an in-
creased use of marginal donors, such as DCD donors. Therefore, it is im-
portant to understand if there is a distinction between the vulnerability
of DCD and DBD grafts to ischemia and reperfusion.
Summers et al. (2010) performed a retrospective analysis of the UK
Transplant Registry in order to assess the factors that affect outcomes
following kidney transplantation of 9134 deceased donor kidney trans-
plants performed between January 1, 2000 and December 31, 2007
(Summers et al., 2010). 8289 (90.7%) were from DBD donors, and the
remaining 845 transplants (9.3%) were extracted from donation after
cardiac death (DCD) donors. The cohorts demonstrated no signiﬁcant
difference in 5-year kidney graft survival (76.4% DBD vs 76.2% DCD) or
primary non-function rates (3% each). However, the incidence of de-
layed graft function (DGF: 24% DBD vs 49% DCD, P b 0.0001) was signif-
icantly higher in DCD grafts. DGF is a type of acute renal failure that
causes post-transplantation oliguria, increased allograft immunogenic-
ity and also increases the risk of acute rejection episodes (Gueler et al.,
2015). Similarly, Gagandeep et al. also undertook an analysis of clinical
outcomes but from US national data (Gagandeep et al., 2006). The
authors reported that both allograft and recipient survival were similar
between DCD and DBD cohorts. However, the risk of delayed graft
function (DGF) was found to be 42 to 51% in DCD recipients in compar-
ison to 24% in DBD grafts. Likewise, Doshi and Hunsicker also found no
signiﬁcant difference in 5-year patient survival (DCD vs. DBD 81.3 vs.
81.8%; P = 0.70) or allograft survival rates (DCD vs. DBD, 66.9 vs.
66.5%; P = 0.52). The risk of DGF, however, was higher in DCD grafts
(DCD vs. DBD, 41 vs. 24%; P b 0.001). Therefore, studies have consis-
tently demonstrated the increased prevalence of DGF in DCD kidney
graft recipients. In the US, between 1985 and 1999, the rate of DGF was
reported at 14.7% (Ojo et al., 1997). The incidence of DGF rose to 23% be-
tween 1998 and 2004 and was concurrent with the increased use of ECD
(Tapiawala et al., 2010). DGF continues to be a major barrier for allograft
survival and requires the compulsory return of the patient to dialysis.
Whilst both DCD and DBD grafts seem to possess similar rates of al-
lograft survival and patient survival, higher rates of DGF in DCD organs
may be due to these grafts being more susceptible to ischemia reperfu-
sion injury (Gobe et al., 1999). Experimental studies have demonstratedReduces Long Term Renal Graft Survival: Mechanism and Beyond,
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following prolonged periods of hypothermic preservation are involved
in the development of delayed graft function (Koo et al., 1998). The gen-
eration of reactive oxygen species (ROS), release of inﬂammatory cyto-
kines and adhesion andmargination of leukocytes are all cellular events
that result in renal injury and subsequent generation of DGF (Schroppel
and Legendre, 2014).
3.2. Ischemia-Reperfusion Injury, Delayed Graft Function and Chronic Allo-
graft Dysfunction
Delayed graft function (DGF) is deﬁned as the failure of the
transplanted kidney to function immediately, hence necessitating
renal replacement therapywithin the ﬁrstweek after surgery. Extended
cold ischemia time is an independent risk factor for the development of
delayed graft function (Quiroga et al., 2006). Prolonged cold ischemia
promotes DGF and acute immune rejection which, in turn, can shorten
long-term graft survival.
Studies investigating the effects of cold ischemia on delayed graft
function (Table 1) have produced conﬂicting results when considering
deceased, living and DCD donors. Earlier ﬁndings produced by Barba
et al. (Barba et al., 2011) found that each hour of cold ischemia increased
the risk of DGF in deceased donor grafts by 10%, however this relation-
ship was only found beyond 18 h of cold ischemia. The authors found
that, not only did cold ischemia under 18 h have little negative impact
on DGF, but also had no negative affect on overall graft survival. These
conclusions were evidenced by 5-year graft survival rates of 91% withTable 1
Clinical study of the impact of IRI on renal graft survival.
Author
(year)
Study design Area of
Barba et al.
(2011)
Prospective analysis of 378 adult renal transplantations Delaye
(DGF)
rejectio
Sert et al.
(2014)
Retrospective analysis of 111 deceased donor adult renal
transplantations (1994–2009)
Delaye
and acu
Krishnan
et al.
(2016)
Retrospective analysis of 3717 living donor renal transplantations
(1997–2012) in patients who had participated in the Australian
Paired Kidney Exchange Program.
Delaye
and ch
dysfun
Kayler et al.
(2017)
Retrospective cohort study of 6276 adult ﬁrst-time kidney-only
recipients of paired kidneys (derived from the same donor
transplanted into different recipients) from donation after
circulatory death (DCD) donors (1998–2013).
Delaye
Chaumont
et al.
(2015)
Retrospective analysis of 1784 deceased donor renal
transplantations (1983–2014)
Delaye
and acu
Kayler et al.
(2011)
Retrospective analysis of 17,514 paired expanded criteria donor (ECD)
renal transplantations (1995–2009)
Delaye
Hellegering
et al.
(2013)
Retrospective analysis of 472 adult living donor renal
transplantations (1996–2010)
Early g
(EGF) a
allogra
Perez
Valdivia
et al.
(2011)
Retrospective analysis of 2525 non-combined cadaveric renal
transplantations (2000–2008)
Early g
and ch
dysfun
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EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018.01.025cold ischemia b18 h and 84% with cold ischemia N18 h. Sert et al. (Sert
et al., 2014) also demonstrated that cold ischemia time was an impor-
tant modiﬁable risk factor in the development of DGF in deceased
donor transplantations, with a higher incidence of DGF in grafts that
had experienced longer cold ischemia time. Importantly, the authors
found that these negative effects were particularly clearly observed in
kidneys with a cold ischemia time between 20 and 30 h, and beyond
30 h. These ﬁndings support those produced by Barba et al. (Barba
et al., 2011) in purporting that there is a speciﬁc threshold for cold is-
chemia to which the development of DGF is associated, with a subse-
quent increase in DGF for each additional hour of cold ischemia. When
considering the effects of DGF on graft survival, it is interesting to note
that there is evidence to suggest that DGF actually has no inﬂuence on
patient or graft survival from deceased donors (Chaumont et al.,
2015). In fact, graft survival was only signiﬁcantly reduced when acute
rejection occurred in combination with DGF. The authors also found
that perioperative saline loading efﬁciently reduced the detrimental ef-
fects of cold ischemia, thus reducing the incidence of DGF.
Despite the apparent evidence to support the ‘threshold’ hypothesis
of cold ischemia, there is also data to indicate that cold ischemia time
below a deﬁned threshold is also associated with DGF and chronic allo-
graft dysfunction when considering living donors.
Krishnan et al. (Krishnan et al., 2016) found that, for recipients who
had received kidneys from living older donors aged N50 years, every
hour of cold ischemia time was associated with adjusted odds of 1.28
for DGF. Furthermore, cold ischemia time of N4–8 h was associated
with adjusted hazards of 1.93 for overall graft loss and 1.91 for death-investigation Conclusions
d graft function
and acute
n
CI b18 h does not negatively impact graft survival. 91% graft survival
with CI b18 h and 84% survival with CI N18 h. After 18 h, each hour
of CI results in a 10% increase in DGF.
d graft function
te rejection
DGF prevalence was 54% and AR prevalence in the ﬁrst year
post-transplantation was 9.9%. Patients with DGF had higher serum
creatinine levels at the ﬁrst, third and ﬁfth years. CI time is an
important modiﬁable risk factor in the development of DGF. There
was no correlation between CI time and AR.
d graft function
ronic allograft
ction
Donor age is an effect modiﬁer between CI time and graft outcomes. For
grafts obtained from donors N50 years, each additional hour of CI time
was associated with adjusted odds of 1.28 for delayed graft function.
d graft function Prolonged CI time has limited bearing on long-term graft outcomes,
in the setting of donation after circulatory death. Death censored
graft survival is comparable between recipients of kidneys with
higher CI time and lower CI time in DCD donor recipients.
d graft function
te rejection
Absence of perioperative saline loading increases acute rejection
incidence (OR = 1.9 [1.2–2.9]). Patient's residual diuresis ≤500
mL/d (OR = 2.3 [1.6–3.5]) and absence of perioperative saline
loading (OR = 3.3 [2.0–5.4]) are risk factors for DGF. DGF has no
inﬂuence on patient and graft outcome, unless occurring in
combination with acute rejection, in which case there is a
signiﬁcant reduction in graft survival.
d graft function Prolonged CI time is a risk factor for DGF among ECD renal
transplants, however DGF has no signiﬁcant effect on ECD graft
survival. Prolonged CI time is associated with a signiﬁcantly
increased incidence of DGF in ECD kidneys (35% vs. 31%, p b 0.001)
including substantially higher rates for CI time differences ≥ 15 h
(42%). No signiﬁcant difference in graft loss between groups with
higher and lower CI (p = 0.47).
raft function
nd chronic
ft dysfunction
Poor EGF had an incidence of 13.7% in living donor kidney allograft
recipients. Patients with poor EGF experienced signiﬁcantly lower
rejection-free and long-term graft survival, compared to those with
immediate graft function.
raft function
ronic allograft
ction
Duration of CI time was signiﬁcantly associated with older donor
and recipient age. Longer CI time was associated with poorer early
graft function, independent of donor and recipient age. Prolonged
CI time produces signiﬁcant worse survival rates; CI time produce
signiﬁcantly worse survival rates for recipients (RR: 1.03,
1.005–1.05, P = 0.02) and grafts (RR: 1.03, 1.01–1.04, P = 0.002).
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ﬁndings indicate that cold ischemia time signiﬁcantly below the sug-
gested threshold of approximately 20 h, as previously demonstrated
by Barba and Sert, may also be associated with an increase in both
DGF and chronic allograft dysfunction in livingdonor recipients. In addi-
tion, donor age also seems to be an effect modiﬁer between cold ische-
mia time and graft outcomes, suggesting that efforts to reduce cold
ischemia time, particularly involving older living donor kidneys, are
necessary to improve graft survival.
To match the rising demand for organs within a limited donor pool,
there has been an increasing use of suboptimal donors, including DCD
donors and expanded criteria donor (ECD) grafts. With regards to the
effects of cold ischemia time on DGF and chronic allograft dysfunction
in DCD donor grafts, the ﬁndings have not correlated with those pro-
duced when investigating living and deceased donors. Kayler et al.
(2017) found that prolonged cold ischemia time, up to 30 h, did not
have any signiﬁcant negative impact on long-term graft survival
outcomes of kidneys from DCD donors. It is important to note that the
authors did identify evidence for an association between prolonged
cold ischemia time and primary non-function, however these ﬁndings
were limited by event rates and differences between groups, thus
warranting further investigation. Interestingly, these ﬁndingswere sim-
ilarwhen considering ECD grafts. ECDgrafts are classically considered to
be suboptimal, whilst the precise deﬁnition of an ECD remains elusive.
An ECD is often thought to be any donor over the age of 60, or a donor
over the age of 50 with two of the following co-morbidities: creatinine
N1.5 mg/dl, hypertension or death following a stroke. Kayler et al.
(2011) found that, whilst prolonged CI time was a risk factor for the de-
velopment of DGF amongst ECD grafts, DGF alone had no signiﬁcant ef-
fect on graft survival. These ﬁndings suggest that, as DGF seems to have
no signiﬁcant effect on graft survival within the ECD pool, ECD grafts
that have traditionally been considered inadequate may, in fact, be via-
ble. Both these studies are limited by the fact that rates of early rejection
were not simultaneously investigated, as rejection has been shown to
be intrinsically related to graft survivalwhen considered in combination
with DGF.
3.3. Ischemia-Reperfusion Injury and Acute Rejection
A wealth of clinical evidence has demonstrated that the severity of
ischemia-reperfusion injury is positively associated with the frequency
of acute rejection episodes. Barba et al. (2011) reported that N18 h of
cold ischemia increased the incidence of acute rejection episodes as
well as early onset of the ﬁrst rejection episode.
The relationship between DGF and acute rejection remains contro-
versial. Recently, Sert et al. (2014) found that there was no association
between cold ischemia time and the incidence of acute rejection. A ret-
rospective cohort study by Perez Valdivia et al. (2011) produced con-
founding results that indicated that longer cold ischemia time was
associated with poorer early graft function, independent of donor and
recipient age. Furthermore, prolonged cold ischemia time was found
to reduce both patient and graft survival rates; longer cold ischemia
time produces signiﬁcantly worse survival rates for recipients (RR:
1.03, 1.005–1.05, P = 0.02) and grafts (RR: 1.03, 1.01–1.04, P = 0.002).
It is important to consider the relationship between acute rejection,
DGF and long-term graft survival. Sert et al. (2014) demonstrated that,
although the prevalence of acute rejection was higher in grafts with
DGF, this association was not statistically signiﬁcant, whilst, in fact,
acute rejection demonstrated no negative effects on overall graft sur-
vival. Overall, the current literature is not conclusive regarding the ef-
fects of acute rejection and poor early graft function on long-term
graft function. Most recently Hellegering et al. (2013), conducted a ret-
rospective cohort study and found that patients with poor early graft
function experienced signiﬁcantly lower rejection-free and long-term
graft survivals, compared to those with immediate graft function, as
supported by two previous retrospective cohort studies (BrennanPlease cite this article as: Zhao, H., et al., Ischemia-Reperfusion Injury
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studies found no signiﬁcant correlation between poor early graft func-
tion and graft survival (Nogueira et al., 2009; Tyson et al., 2010). As pre-
viously discussed, it is interesting to note that these confounding results
may, at least in part, be explained by recent ﬁndings that indicate that
acute rejection alone may not detrimentally effect graft survival unless
occurring in combination with DGF (Chaumont et al., 2015).
Taking this evidence into account, it is possible that suppressing
ischemia-reperfusion injury may decrease acute immune rejection epi-
sodes, whilst prevention of acute rejection within the ﬁrst year may
postpone later allograft failure. However, due to the confounding results
within the literature, further investigation of the association between
cold ischemia time, acute rejection and long-term graft survival is cer-
tainly warranted.
4. Impact of IRI on Renal Graft Survival: Hypothesis andMechanisms
Whilst transplanted kidneyswith prolonged ischemia time aremore
susceptible to long-termdeterioration, the exactmolecularmechanisms
underlying this association remain to be characterized. We will review
several hypotheses that seek to explain the relationship between early
IRI and later graft loss.
4.1. Ischemia-Reperfusion Injury and Immunogenicity of the Renal Graft
The injury theory proposes that ischemia-reperfusion injury aug-
ments graft immunogenicity. This is based on the observed correlation
between the degree of IRI insult and the subsequently increased distur-
bance of adaptive immunity and the greater possibility of immunologic
recognition and graft rejection (Perico et al., 2004).
4.1.1. IRI and the Recognition of Allograft
Rejection of the renal allograft is initiated by immune recognition of
foreign antigens. The immune recognition of allografts ismediated by T-
cell receptors and alloantibodies (van der Merwe and Dushek, 2011).
There are three distinct pathways of T-cell allorecognition. The ﬁrst is
the direct pathway which occurs when T-cells recognize endogenous
peptides displayed in the context of donor MHC molecules on the sur-
face of donor antigen-presenting cells (APCs). The second pathway is
the indirect pathway, in which recipient T-cells recognize donor pep-
tides presented on MHC molecules on the surface of recipient DCs
(Benichou and Thomson, 2009). In this case, recipient DCs have taken
up and processed antigens that have been released or shed by donor
cells. The third pathway is the semi-direct pathway, which has been
more recently identiﬁed as a mechanism by which recipient-derived
APCs present allopeptides in the context of self-MHC (indirect path-
way), in addition to acquired allo-MHC-peptide complexes (direct
pathway).
The direct immune response against the graft is initiated by an in-
ﬂammatory response that occurs when damaged or dying cells release
endogenous adjuvants, referred to as damage-associatedmolecular pat-
terns (DAMPs), and by the secretion of pro-inﬂammatory cytokines
from distressed cells (Bianchi, 2007). Inﬂammatory DAMPs, including
Heat-Shock proteins (HSP), HMGB-1 and DNA fragments, are recog-
nized by speciﬁc receptors such as TLR-2 and TLR-4 which, in turn, trig-
ger inﬂammatory and cytotoxic responses (Park et al., 2004). This
frequently occurs in solid organ grafts after IRI because, as apoptotic
cells are not rapidly cleared following the initial injury, secondary ne-
crosis occurs due to loss of membrane integrity, resulting in the release
of DAMPs (Dong et al., 2007). The massive release of pro-inﬂammatory
cytokines, such as IL-1α and tumour necrosis factor (TNF), from dam-
aged cells during ischemia-reperfusion injury causes donor DCs to be-
come activated and migrate from the donor graft to the recipient
lymph nodes and spleen, thus sensitizing recipient T-cells and stimulat-
ing T-cells via the direct pathway (Li and Okusa, 2010; Dong et al.,
2007). A study by Dong et al. (2007) provides evidence that residentReduces Long Term Renal Graft Survival: Mechanism and Beyond,
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tion of TNF during early renal ischemia-reperfusion injury.
The indirect pathway is initiated when recipient DCs take up mate-
rial from dead and dying cells. This material is subsequently processed
and presented to indirect-speciﬁc T-cells, which migrate into the graft
and cause cellular damage, either by direct cytotoxicity (CD8), or by fa-
cilitating cytokine release from activated CD4+ cells. CD4+ T-helper
cells can be subdivided into Th1 and Th2, which produce Th1-type cyto-
kines and Th2-type cytokines respectively. Th1-type cytokines, such as
interferon-α, induce pro-inﬂammatory responses, whilst Th2-type cy-
tokines, such as IL-4, 5 and 13, are associated with ﬁbrotic tissue depo-
sition and interleukin-10, which is anti-inﬂammatory.
In addition to the direct and indirect pathways, it is also important to
consider the role of the semi-direct pathway of T-cell allorecognition.
Following engraftment, recipient-derived APCs inﬁltrate the allograft
and, as well as presenting allopeptides indirectly, also present alloge-
neic MHC-peptide complexes directly by acquiring donor complexes
from donor-derived cells or tissues (Smyth et al., 2008). This process
is known as ‘cross-dressing’ and is thought to encourage a continued di-
rect alloimmune response for a prolonged period following death of
donor-derived APCs. It has recently been demonstrated that acquired
allo-MHC-peptide complexes on recipient dendritic cells are able to
promote allograft rejection indeﬁnitely, even following the termination
of the direct pathway and in the absence of cross-presentation (Smyth
et al., 2017). Nonetheless, the precise role of the semi-direct pathway
in the development of allograft rejection remains to be elucidated.
Laboratory studies have shown that renal IRI results in the long-term
inﬁltration of activated and effector-memory T-lymphocytes, whilst the
expression of the effector-memory phenotype by inﬁltrated lympho-
cytes indicates that these lymphocytes are responding to an injury-
associated antigen (Ascon et al., 2009). The presence of inﬁltrating T
cells could be due to the direct, indirect or semi-direct pathway of
allorecognition. The direct pathway predominates in early acute allo-
graft rejection, as there are a large number of donor DCs expressing a
high level of MHC molecules and direct allospeciﬁc T-cells present in
the graft. Later, as the number of donor DCs is gradually depleted, the
T-cell mediated indirect pathway begins to dominate and is considered
the main pathway in chronic rejection (Benichou et al., 2011).
IRI can inﬂuence these processes in various ways. Firstly, graft
ischemia-reperfusion injury can promote indirect allo-recognition by
providing antigens thatmay be readily taken up andprocessed in the in-
direct pathway.
Secondly, DCmigration is increased during ischemia-reperfusion in-
jury, which promotes the migration of T-cells (Jurewicz et al., 2010). T-
cells migrate into the renal transplant graft and differentiate into effec-
tor T-cells, which include CD8+ cytotoxic T-cells and CD4+ T helper
cells.
Thirdly, IRI may promote a shift in cytokine proﬁles at the moment
of engraftment, which could critically affect renal allograft rejection
and tolerance (Strom, 2004) through activating different T-cell popula-
tions. During IRI, activated macrophages inﬁltrating the renal graft are
capable of producing IL-1, IL-6, IL-12 and IL-23 (Li and Okusa, 2006),
so it is naturally postulated that the pro-rejection response is shifted,
which augments graft damage. It is clear that ischemia-reperfusion
manifests a particular type of immune response, which shifts the bal-
ance towards a pro-inﬂammatory Th1 and Th17 response, rather than
an anti-inﬂammatory regulatory T-cell (Treg) response. Th17 cells are
capable of producing pro-inﬂammatory cytokines, such as IL-17A, IL-
17F and IL-21, and chemokines, such as CXCL1, CXCL2, CCL2 (Tesmer
et al., 2008), whilst Tregs are immunosuppressive lymphocytes and
their actions aremediated by the production of anti-inﬂammatory cyto-
kines, such as IL-10 or TGF-β (Kinsey et al., 2009). Activation and pre-
domination of Th1 and Th17 responses over the T-reg response results
in the recruitment of other inﬂammatory cells, including neutrophils
andmonocytes, at the site of inﬂammation, therefore contributing to al-
lograft rejection (Chadha et al., 2011).Please cite this article as: Zhao, H., et al., Ischemia-Reperfusion Injury
EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018.01.025Finally, it has also recently been demonstrated that renal IRI may
promote the humoral immune response by amplifying antibody me-
diated rejection (Fuquay et al., 2013). Therefore, following IRI, an
antigen-speciﬁc ampliﬁed IgG response may be generated in the
presence of an alternative functional complement pathway.
Taken together, the initial vigorous cell death initiated by IRI causes
the massive release of DAMPs, and induces a heavy inﬂux of inﬂamma-
tory cells, such as neutrophils and macrophages. This in turn results in
tubular cell injury and produces further cellular components that are
readily presented by MHC molecules on dendritic cells and macro-
phages, accelerating antigen processing and presentation, and facilitat-
ing T-cell recognition. The inﬂammatory milieu established during
reperfusion injury attracts more T-cells to the ‘danger’ zone and there-
fore promotes their activation, differentiation and cytotoxic actions
(Fig. 1).4.2. Ischemia-Reperfusion Injury and Loss of Renal Mass
The hyperﬁltration theory by Brenner et al. (1996) highlighted
the role of chronic hemodynamic changes in renal failure. Glomeru-
lar hyperﬁltration has been deﬁned as GFR of more than two stan-
dard deviations above the mean GFR of healthy individuals (Sasson
and Cherney, 2012). The threshold for glomerular hyperﬁltration
ranges from 125 ml/min/1.73 m2 to 175 ml/min/1.73 m2 (Dahlquist
et al., 2001; Amin et al., 2005). Increased ﬁltration per nephron is
an adaptive response of the remaining nephrons to meet the excess
load. Studies have demonstrated that functional absence of one kid-
ney results in an adaptive increase in contralateral renal blood ﬂow
and a decrease in renal vascular resistance; these hemodynamic
changes might be mediated by the NO system (Sigmon et al.,
2004). As such, a 30–70% increase in glomerular ﬁltration rate
above control values is usually observed in the remaining kidney
(Shohat et al., 1991). After loss of renal mass through injury, the re-
maining renal tissue compensates with hyperplasia (increase in cell
number) and hypertrophy (increase in cell volume). It has been
demonstrated that the compensatory growth response is initiated
immediately after unilateral nephrectomy (Helal et al., 2012). Stud-
ies in rodents have demonstrated that the extent of compensatory
growth correlates closely with the amount of renal tissue that is sur-
gically removed (Santos et al., 2006), which has important implica-
tions in the case of IRI with severe reduction in the size of the
nephron population. An increase in glomerular ﬁltration rate at the
level of single nephrons has been demonstrated following gradual
reduction of renal mass (Metcalfe, 2007). Accumulating clinical evi-
dence demonstrates that glomerular hyperﬁltration occurs in the
majority of grafts (Seun Kim et al., 2002) in later years. Giral et al.
(2005) investigated the effects of graft mass on the long-term out-
come of cadaveric kidney grafts of 1142 recipients. Patients with
moderate renal mass reduction demonstrated renal hyperﬁltration,
whilst the kidney grafts with optimal renal mass improved their ﬁl-
tration rate continuously for the entire 4-year period.
Reduction of the functional nephron population by ischemia-
reperfusion injury results in an elevated workload for the remaining
renal mass, and compensatory hyperplasia and hypertrophy in the
renal graft (Fiorina et al., 2005). These compensatory morphological
and functional changes are temporarily adequate to maintain electro-
lyte andwater balance and prevent the development of renal functional
insufﬁciency (Devarajan, 2006). However, functional overloading
could easily exhaust the remaining nephrons and result in sub-
optimal efﬁciency of blood ﬁltration. Gradual accumulation of toxic
metabolites would elevate the oxidative stress and inﬂammatory re-
actions within the grafts, in turn resulting in further reduction of
functional renal mass and further functional overloading. Chronic
renal functional impairment then develops until end-stage graft fail-
ure occurs (Fig. 2).Reduces Long Term Renal Graft Survival: Mechanism and Beyond,
Fig. 1. Ischemia-reperfusion injury and allo-immune response. During renal graft ischemia-reperfusion injury (IRI), (A) renal cell necrosis releases DAMPmolecules such as High-mobility
group box1 protein (HMGB1),which are recognised by receptors, such as receptor for advanced glycation end products (RAGE) andToll-like receptors-2, 4, and 9 (TLR-2, 4 and 9), reactive
oxygen species (ROS) and inﬂammatory cytokines, such as TNF, leading to immune cell activation. (B) Inﬂammatory cells produce and release pro-inﬂammatory chemokines (e.g. CXCL1,
CXCL2) and cytokines (e.g. IL-1 and 6) and promote tissue inﬂammation, inﬁltration of monocyte and neutrophils. (C) Inﬁltrating monocytes produce ROS and inﬂammatory cytokines
such as TNF, enhance the necroptosis in the epithelial cells (D) Renal cells undergoing necrosis could lead to the release of donor antigens. They are presented by donor antigen
presenting cells (APC) and stimulated T-cells. This is direct allo-recognition. (E) As the number of donor antigen presenting cells gradually decreases, the recipient APCs process and
present the antigens to T-cells, leading to indirect allo-recognition. (F) The inﬂammatory milieu formed during IRI inﬂuences the activation and differentiation of T-cells, such as CD8+
T-cells, CD4+ Th1 and Th2 cells, Treg cells, Tfh cells and Th17 cells, which contribute to either rejection or tolerance of the renal grafts.
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Studies in renal grafts have shown that tubulointerstitial damage,
rather than glomerular change, determines graft functional decline.
Nangaku (2006) proposed chronic hypoxia in the tubulointerstitium
as a common pathway for renal failure. This chronic hypoxic theory
states that chronic oxygendeprivation to the tubulointerstitial compart-
ment, caused by compromise of the postglomerular capillary circula-
tion, is responsible for the scarring process. In the case of kidney
transplantation, microvasculature damage and dysfunction, initiated
during ischemia-reperfusion injury, creates a hypoxic environment
that triggers a ﬁbrotic response in tubulointerstitial cells which ulti-
mately results in graft failure.4.3.1. Ischemia-Reperfusion Injury and Graft Vascular Damage
The renal cortex has an average pO2 of approximately 30 mmHg,
whilst oxygen tension in the renal medulla does not rise above
10mmHg (Chen et al., 2009). The effects of limited O2 supply are aggra-
vated by the high O2 demand associated with the high tubular O2 con-
sumption necessary for solute exchange and the high rate of aerobic
glycolysis. Under pathological conditions, the delicate balance of oxygen
supply compared to demand is disturbed. As a result, the kidney is
highly susceptible to hypoxic injury.Please cite this article as: Zhao, H., et al., Ischemia-Reperfusion Injury
EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018.01.025Adequate reperfusion in the graft is vital for renal functional recov-
ery by reducing hypoxic tissue injury. Upon reperfusion, it has been
demonstrated that the renal blood ﬂow is only partially restored, with
a consistent reduction in total ﬂow of up to 50% after reperfusion
(Sutton et al., 2002; Molitoris and Sutton, 2004). The failure of blood
to reperfuse a temporarily ischemic area after the physical obstruction
has been removed or bypassed was described as the “no-reﬂow” phe-
nomenon (Rezkalla and Kloner, 2002). It was suggested that an uncon-
trolled and inappropriate release of various inﬂammatory mediators,
leading to direct cytotoxic effects on endothelial cells, impairsmicrovas-
cular autoregulation of blood ﬂow. In addition, it was reported that in
the post-ischemic kidney, increased oxidative stress leads to an imbal-
ance of vasodilatory and vasoconstrictive mediators in the endothelium
and epithelium of the kidney (Legrand et al., 2008). Renal arterioles ex-
hibit impaired vasorelaxation in response to vasodilators, such as ace-
tylcholine (ACh), and increased responsiveness to vasoconstrictive
agents including endothelin, angiotensin II, thromboxane A2, leukotri-
ene C4 and endothelium-derived prostaglandin H2. The tonic modula-
tion of renal ﬂow is also disturbed through excessive vascular
constriction (Legrand et al., 2008). Damage to both endothelial and
smooth muscle cells occurs rapidly after ischemic insult. Upon reperfu-
sion, blood ﬂow can be impaired in peritubular capillaries due to endo-
thelial cell rupture or congestion. The interstitial oedema compresses
capillaries, narrows the vascular lumen and increases blood ﬂowReduces Long Term Renal Graft Survival: Mechanism and Beyond,
Fig. 2. Loss of functional mass during renal graft ischemia-reperfusion injury. Renal graft ischemia-reperfusion injury promotes abnormal cellular changes that result in the gradual loss of
functional kidneymass. The pathophysiology of ischemia-reperfusion injury is complex and can potentiate graft damage both acutely and chronically due to a variety of cellular and tissue
changes that can manifest clinically. On a cellular level, ischemia results in the predominance of anaerobic processes and subsequent cellular damage via processes such as protease
activation and N+/K+ transport defects. The associated reperfusion injury occurs due to the restoration of oxygen supply to the graft, resulting in a potpourri of cellular changes
including the generation of reactive oxygen species and the upregulation of inﬂammatory cytokine pathways. The cellular responses during ischemia and reperfusion injury result in
abnormal changes within renal tissue, with many of these processes acting synergistically to cause the gradual loss of functional renal mass. The cellular and tissue responses result in
graft damage that is exhibited clinically in the form of acute renal necrosis, vasculitis and failure. A less familiar clinical feature of ischemia-reperfusion injury is chronic allograft
dysfunction, which predominantly occurs due to abnormal immune activation and the subsequent deterioration in functional graft mass.
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augment endothelial damage by sustaining the inﬂammatory and cyto-
toxic response. Pro-inﬂammatory cytokines released during IRI activate
the coagulation pathways, which contributes to microcirculatory dys-
function by capillary congestion, resulting in severe compromise of
local and global renal perfusion (Hoffmann et al., 2005; Sharfuddin
et al., 2009).
In addition to hypoperfusion, hypovascularization is another conse-
quence of ischemia-reperfusion-associated vascular damage. It was
demonstrated that the number of peritubular capillaries in human
renal biopsies declines with progressive loss of renal function (Steegh
et al., 2011). Capillary density declines rapidly within days of the initial
insult and persists for weeks, in parallel with an increase in peritubular
matrix deposition (Steegh et al., 2011). The inﬂammatory response and
oxidative stress-induced endothelial cell death are responsible for
vascular regression and increased deposition of ﬁbrotic tissues due to
hypoperfusion. This could also compress and damage the
microvasculature.
In the long-term survival of grafts, pathological examination of graft
vasculature has revealed a broad spectrum of abnormalities, ranging
from ﬁbrous intimal thickening to complicated atherosclerotic plaques;
this is termed graft vascular disease (Mitchell, 2009). Shortly after
transplantation, focal ﬁbrous intimal thickening and vasculitis predom-
inates. This develops into chronic allograft vasculopathy, manifested as
focal atherosclerotic plaques or diffuse intimal thickening. The cellular
components of intimal proliferative lesions consist of endothelial cells,
smooth muscle cells, macrophages and T-lymphocytes (Skaro et al.,
2005; Kitchens et al., 2007). Graft vascular disease usually involves the
entire length of the transplanted arterial vasculature, including pene-
trating intraparenchymal arterioles (Mitchell, 2009). Blood ﬂow resis-
tance increases 16-fold, with a 50% reduction in the luminal radius
(Mitchell and Libby, 2007). Therefore, arterial remodelling could se-
verely compromise graft perfusion, whilst occlusion of arterioles could
result in stellate infarcts, which may develop into ﬁbrotic lesions
(Huibers et al., 2011). Studies have shown that ischemia-reperfusion in-
jury accelerates the development of graft vascular disease and the early
ischemia-associated recruitment of neutrophils. In addition, thesePlease cite this article as: Zhao, H., et al., Ischemia-Reperfusion Injury
EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018.01.025studies demonstrate that macrophages can provide a pro-
inﬂammatory environment that supports the allograft-speciﬁc immune
response against the vasculature. Macrophages and T-cells in the
alloresponse stage produce additional cytokine mediators and, in com-
bination with antibody-mediated responses, induce widespread endo-
thelial and medial smooth muscle injury (Wehner et al., 2007).
Interferon-α, produced by inﬁltrating macropahges, exerts potent ef-
fects on inﬂammatory and smooth muscle cell activation and
recruitment.
4.3.2. Ischemia-Reperfusion Injury and Hypoxia-Fibrosis Response
The decreased vascular density and increased vascular dysfunction
associated with ischemia-reperfusion injury promotes chronic renal
graft hypoperfusion, which causes persistent regional hypoxia. Hypoxia
is a potent proﬁbrogenic stimulus for tubular epithelial cells, interstitial
ﬁbroblasts and renal microvascular endothelial cells (Norman et al.,
2000). In response to a low pO2, there is an accumulation of extracellu-
lar matrix (ECM) proteins as a result of both increased matrix synthesis
and decreasedmatrix degradation, mediated by a decreased expression
of matrix metalloproteinases (MMPs) (Fine et al., 2000). Hypoxia
induces complex changes in the expression of a large number of genes
involved in cell survival and adaptation. In tubular epithelial cells, hyp-
oxia also induces the expression of ﬁbrogenic factors, including
Transforming Growth Factors and Endothelin-1 (Yamashita et al.,
2001). Hypoxia promotes a ﬁbrogenic phenotype in ﬁbroblasts, which
is characterized by increased proliferation, enhanced myoﬁbroblast
differentiation and contraction and altered ECM metabolism (Norman
et al., 2000). In addition to increased ECM production, hypoxia
suppresses matrix degradation by decreasing the activity of matrix
metalloproteinases, in particular interstitial collagenase matrix
metalloproteinase-1 (Fine and Norman, 2008).
Chronic hypoxia may potentiate the inﬂammatory response by pro-
viding the chemotactic stimulus that drives immune cell recruitment
and migration at sites of injury (Nizet and Johnson, 2009). In addition,
it has been suggested that inﬂammatory cells, such as macrophages,
contribute to pathological extracellular matrix accumulation (Ko et al.,
2008). Although the mechanisms of cell recruitment and retentionReduces Long Term Renal Graft Survival: Mechanism and Beyond,
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seems plausible as inﬂammatory cells preferentially migrate to hypoxic
sites (Li et al., 2010).
Histologic analysis of chronically scarred kidneys reveals the loss of
microvasculature in the ﬁbrotic bands of collagen and ECM (Norman,
2006). The hypovascularised and hypoperfused regions are formed
after the initial ischemia-reperfusion injury. The cells around the
edges of such regions are subjected to prolonged hypoxia and develop
mitochondrial functional impairment. This results in persistent energy
deﬁcits and subsequently causes cells to be replaced by connective tis-
sue after undergoing apoptosis. The vicious cycle of ﬁbrogenic response
is established, leading to the obliteration of more capillaries and more
ﬁbroid lesions (Fig. 3).
5. Summary of the Hypotheses
The renal graft needs to carry the workload of two previously intact
kidneys. However, this workload must be fulﬁlled despite a rapidly
diminishing pool of functioning nephrons due to ischemia-reperfusion
injury, as well as episodes of acute rejection and hypoperfusion-
induced hypoxic injuries, in addition to inﬂammation and graft vascular
disease. Various pathological processes act collectively to contribute to
the development of graft failure. Activation of the immune response re-
sults in the loss of renal function, which culminates in signiﬁcant hae-
modynamic stress. This, in turn, causes additional cellular injury and
inﬂammation, acting in a vicious cycle to further promote immune
activation.
Extensive ablation of renal mass initiates a rapidly progressive
course of hemodynamically-mediated glomerular injury and renal func-
tional impairment. Thus, we propose that the critical effect of ischemia-
reperfusion injury on graft survival is its initiation of renalmass ablation
by increasing renal parenchymal destruction, enhancing graft immuno-
genicity, increasing vascular damage and expanding ﬁbrotic lesions.
Therefore, protecting the renal graft against ischemia-reperfusion injuryFig. 3.Graft vascular injury during renal graft ischemia-reperfusion injury. Renal graft vascular i
injury. Endothelial vasoconstriction and necrosis occurs during periods of prolonged ischemi
ischemia, due to an increase in the intrarenal activity of vasoconstrictors and a deﬁciency o
intrarenal hypoxia, thus exacerbating tubular injury and potentiating acute tubular necrosis w
resulting in ﬁbrin deposition and platelet aggregation in peritiubular and glomerular capillari
decreased glomerular ﬁltration rate. Red blood cells and leukocytes adhere to the vascular en
platelet plugs containing ﬁbrin can cause tubular obstruction and increased tubular press
microvasculature damage promotes the coagulation cascade during reperfusion. Thromboses
failure.
Please cite this article as: Zhao, H., et al., Ischemia-Reperfusion Injury
EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018.01.025would slow the tempo of chronic renal graft failure by preserving the
nephron supply, decreasing graft immunogenicity and protecting the
intra-organ microvasculature.
6. Impact of IRI on Renal Graft Survival: Novel Protective Strategies
Recently, new strategies targeting renal graft IRI have shown promis-
ing results in extending the survival of renal grafts after transplantation.
6.1. Machine Perfusion
In order to ensure the best possible function of the organ following
transplantation, two methods of organ preservation are currently used
in clinical practice: static cold storage and machine perfusion. Recent
studies investigating machine perfusion have demonstrated its beneﬁ-
cial effects in suppressing renal graft IRI.
6.1.1. Hypothermic Machine Perfusion
An alternative to ex vivo hypothermic ischemic preservation is the
use of hypothermic machine perfusion (HMP). This process involves
the introduction of a cooled perfusion solution into an enclosed system
through the organ's vascular bed under a deﬁned pressure, therefore
partially emulating natural perfusion. Many studies have been per-
formed to assess the renoprotective efﬁcacy of cold storage vs. HMP.
Moers et al. conducted a multi-centre, international randomized study
in a group of 336 kidney pairs, one of which was preserved using cold
storage and the other with HMP (Moers et al., 2009). The study showed
a signiﬁcant reduction in DGF risk from 26.5% to 20.8% with HMP, as
well as an increase in one-year graft survival from 90% to 94% compared
to cold storage. In patients who received a kidney following cold stor-
age, DGF signiﬁcantly reduced three-year transplant survival compared
to kidneys stored with HMP, whilst a DGF episode had a much smaller
effect on overall transplant survival. Wszola et al. conducted a prospec-
tive study whereby 69 kidney biopsy specimens were collected with anjury is a common occurrence following renal transplantation due to ischemia-reperfusion
a. Vasoactive hormones may be responsible for the haemodynamic abnormalities during
f vasodilators. This ultimately results in a reduction in renal blood ﬂow and persistent
ithin the transplanted kidney. During reperfusion, pro-coagulant pathways predominate,
es. These processes can cause microthromboses, leading to impaired renal perfusion and
dothelium, further contributing to the blockage of renal blood vessels. The formation of
ure, it is thought that the exposure of tissue factor to the subendothelium following
within the renal vasculature of the transplanted graft promote tubular necrosis and graft
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that machine perfusion has the ability to mediate hypoxia-related gene
expression, thus potentially improving long-term graft survival. As
discussed in a recent review by de Deken et al. (2016), there is still con-
siderable debate regarding the optimum settings for hypothermic ma-
chine perfusion. Despite this, there is signiﬁcant evidence to support
its use in clinical practice, particularly in relation to expanded criteria
donors (ECDs) (Moers et al., 2009; Treckmann et al., 2011).
6.1.2. Normothermic Machine Perfusion
A novelmethod of organ preservation that has recently been studied
is normothermic machine perfusion (NMP). Theoretically, NMP has the
beneﬁt of reducing hypothermia-related graft damage, as well as en-
abling good assessment of ischemic organ damage. Whilst progress
has been made in NMP, mainly in experimental settings, there are lim-
ited clinical studies investigating whether these ﬁndings can be trans-
lated in human organs. Hosgood and Nicholson (2011) published the
ﬁrst report on NMP of a human kidney graft and, in their subsequent
paper of 18 kidneys from ECDs (Nicholson andHosgood, 2013), demon-
strated that NMP-stored grafts possessed a signiﬁcantly lower rate of
DGF (5.6%) compared to the cold storage control group (36.2%). Since
then, Hosgood and Nicholson subsequently transplanted a pair of DCD
kidneys previously rejected for transplantation by all UK transplant cen-
tres due to poor perfusion (Hosgood et al., 2016). Patchy areas were
cleared in both kidneys during 60min of NMP and the graftswere even-
tually transplanted, resulting in immediate graft function. Following
these successful studies, Hosgood has begun conducting a UK-based
phase II multicentre trial recruiting 400 patients in order to compare
pre-transplant NMP and conventional cold storage, with results ex-
pected by 2020 (Hosgood et al., 2017).
6.2. Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are self-renewing, multipotent
cells, with numerous studies indicating that exogenous administration
of MSCs has the ability to attenuate renal ischemia reperfusion injury
and promote renal repair (Peired et al., 2016).MSCs are thought to facil-
itate various cellular processes by mediating the release of soluble fac-
tors (Galderisi and Giordano, 2014). These processes include
immunomodulation via IL-6, IL-8, and MCP-1 release (Casiraghi et al.,
2014; Squillaro et al., 2016; Liechty et al., 2000), extracellular matrix re-
modelling via the modulation of ﬁbronectin, collagen and
metalloproteinase-mediated processes (Ries et al., 2007; Togel et al.,
2005b; Goransson et al., 2004; Liu et al., 2013), and alterations in
growth factors and regulators, including vascular endothelial growth
factor (VEGF) (Togel et al., 2009; Schrijvers et al., 2004), insulin-like
growth factor 1 (IGF-1) (Imberti et al., 2007; Zhang et al., 2004), and he-
patocyte growth factor (HGF) (Chen et al., 2011). MSC-mediated
microvesicle release has also been shown to enhance cell survival and
attenuate programmed cell death processes (Bruno et al., 2012, 2009).
Overall, numerous studies have demonstrated that exogenous adminis-
tration of MSCs attenuates renal ischemia-reperfusion injury (Du et al.,
2013; Bruno et al., 2009; Togel et al., 2005a; Jiang et al., 2015; Dufﬁeld
and Bonventre, 2005; Monteiro Carvalho Mori Da Cunha et al., 2015;
Dufﬁeld et al., 2005) and, therefore, may be a potential future
renoprotective strategy.
6.3. Gas as Ex Vivo Preservation Supplement
Ex vivo preservation is commonly performed in hypothermic condi-
tions in the presence of preserving solutions, such as University ofWis-
consin (UW) solution saturated with nitrogen. However, in recent
years, efforts have been made to limit ischemia-reperfusion injury in
renal grafts during ex vivo preservation by using preserving solutions
saturated with alternative gases.Please cite this article as: Zhao, H., et al., Ischemia-Reperfusion Injury
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Argon is an inert noble gas that has demonstrated neuroprotective
and, more recently, renoprotective properties (Loetscher et al., 2009).
Irani et al. found that cold-storage with argon improved kidney recov-
ery in comparison to mediums containing nitrogen or air (Irani et al.,
2011). It has, therefore, been suggested that argon may provide an
organoprotective environment for kidney transplantation by preserving
organ quality and function.
6.3.2. Xenon
Ma et al. (2009) have demonstrated that xenon preconditioning has
the potential to confer renoprotection against IRI. Xenon, which shares
similar molecular and chemical characteristics with argon, demon-
strated an increased efﬁciency of HIF-1α translation via modulation of
themammalian target of rapamycin pathway. Xenon providedmorpho-
logic and functional renoprotection in a model of renal ischemia-
reperfusion injury, and the study's results suggested that xenon precon-
ditioning acted as a natural inducer of HIF-1α. Therefore, the adminis-
tration of xenon prior to renal ischemia could potentially prevent
acute renal failure and be beneﬁcial in the clinical setting during proce-
dures that temporarily interrupt renal perfusion. In addition to precon-
ditioning, it has also demonstrated the ability for xenon-saturated
preserving solution to protect renal grafts during ex vivo preservation
(Zhao et al., 2013). Grafts stored in xenon-saturated preservative solu-
tion possessed signiﬁcantly less severe histopathologic changes and re-
duced B-cell lymphoma (Bcl-2) and heat shock protein expression.
Following engraftment in Lewis rat recipients, there was a reduction
in macrophage inﬁltration, ﬁbrosis and a signiﬁcant improvement in
renal function in the xenon-treated grafts. Clinically, xenon has the po-
tential to enhance themarginal donor pool of renal grafts by improving
graft survival following ischemia during ex vivo preservation.
6.3.3. Carbon Monoxide
Nakao et al. (2008) demonstrated the ability of carbon monoxide
(CO) in preserving solution to reduce donor-kidney injury after cold
storage (Nakao et al., 2008). The ﬁndings suggest that CO prevents an
increase in heme content within the kidney by inhibiting the degrada-
tion of cytochrome P450 heme proteins, thus eliminating the inﬂamma-
tory effects of excessive heme within the graft. Long-term effects of CO
exposure remain to be elucidated and further studies are necessary to
evaluate long-term graft survival post-treatment.
6.3.4. Hydrogen Sulphide
Recent evidence suggests that hydrogen sulphide (H2S) has a pro-
tective role against renal ischemia-reperfusion injury. The premise be-
hind the renoprotective effects of H2S are linked to its intrinsic role in
renal physiology, such as mediating urinary sodium excretion. Numer-
ous in vivo and ex vivo studies have proposed that H2S induces a variety
antiapoptotic (Xu et al., 2009; Tripatara et al., 2008; Lobb et al., 2014),
anti-inﬂammatory (Hunter et al., 2012; Tripatara et al., 2008), and anti-
oxidant effects (Bos et al., 2013; Simon et al., 2011; Xu et al., 2009), thus
attenuating renal ischemia reperfusion injury associated with patho-
physiological processes such as acute kidney injury and following
renal transplantation. Whilst there is signiﬁcant evidence to indicate
the renoprotective effects of H2S against renal ischemia-reperfusion in-
jury, further studies are required to elicit whether H2S ex vivo preserva-
tion would be a viable option in clinical practice, with regards to both
efﬁcacy and safety.
7. Conclusion
Ischemia-reperfusion injury during renal transplantation continues
to be a signiﬁcant challenge inmaintaining organ function and preserv-
ing graft viability. Despite improvements in immunosuppression, long-
term graft survival rates remain far from ideal. This suggests that im-
mune rejection is not the sole cause of chronic graft failure, but canReduces Long Term Renal Graft Survival: Mechanism and Beyond,
10 H. Zhao et al. / EBioMedicine xxx (2018) xxx–xxxalso be precipitated by factors such as IRI. An intrinsic link between
prolonged ischemic times and delayed graft failure has been
established, as well as an association between the severity of IRI and
the frequency of acute rejection episodes.
8. Outstanding Questions
Despite improvements in graft survival rates, overall long-term sur-
vival still remains modest, particularly when considering the increasing
demand for renal allografts within an already depleted donor pool.
Whilst the association between delayed graft failure and poor long-
term graft survival is well-established, due to confounding results
within the current literature, further investigation of the relationship
between cold ischemia time, acute rejection and long-term graft sur-
vival is warranted. In addition, although investigation of alternative
renoprotective agents such as xenon, argon, carbon monoxide and hy-
drogen sulphide has produced promising results, further pre-clinical
studies are required in order to enhance our understanding of the
long-term effects of these agents on both the transplanted organ and
body's systemic response to them. Furthermore, promising novel thera-
pies such as the exogenous administration of mesenchymal stem cells
also require signiﬁcant further investigation. Obtaining a better under-
standing of the efﬁcacy and safety proﬁle of these agents and therapies
should facilitate the progression of pre-clinical to well-powered, high
quality clinical studies.
9. Search Strategy and Selection Criteria
This is a narrative review exploring the long-term effects of ischemia
reperfusion injury and prolonged cold ischemic times on renal graft sur-
vival. Pubmed was used as database for literature search and kidney
graft ischemia-reperfusion injury were used as key words. Studies in-
vestigating the effects of cold ischemia on renal graft rejection, delayed
graft failure and overall graft survival within the last six years were eli-
gible for inclusion in the review of clinical data. Abstracts were not con-
sidered unless full study reports were available.
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